Next generation relaxin molecular probes and therapeutics

下一代松弛素分子探针和疗法

• 批准号: nhmrc : GNT1117483
• 负责人: Prof John Wade
• 金额: $ 76.38万
• 依托单位国家: 澳大利亚
• 项目类别: Research Fellowships
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/generation-relaxin-molecular-probes-therapeutics/1347032
• 关键词: Next; generation; relaxin; molecular; probes

The peptide hormone relaxin is poised to be the first new treatment for acute heart failure in more than 40 years. However, like other therapeutic peptides, it has a very short duration of action due to its rapid clearance by the body. My work will utilize powerful medicinal chemistry methods to develop new analogues of relaxin that have much longer action by complexing it with sugar or making relaxin polymers. I will also produce smaller relaxin analogues that will be cheaper to manufacture.

肽激素松弛素有望成为40多年来第一个治疗急性心力衰竭的新方法。然而，与其他治疗性肽一样，由于其被身体快速清除，因此其作用持续时间非常短。我的工作将利用强大的药物化学方法开发新的松弛素类似物，通过将其与糖复合或制备松弛素聚合物来发挥更长的作用。我还将生产更小的松弛素类似物，制造成本更低。